AOD-9604
Symbol Ao · MW 1815 Da
C-terminal fragment of human growth hormone studied for fat metabolism.
- Discovered
- 2001
- Half-life
- 3 minutes
- Approval
- Not FDA-approved for weight loss
Quick facts
- Category
- Weight Loss
- Route
- Injectable
- Molecular weight
- 1815 Da
- Half-life
- 3 minutes
- Discovered
- 2001
- Approval status
- Not FDA-approved for weight loss
Reported effects
- Fat oxidation
- Cartilage support
- Lean composition
Overview
AOD-9604 is a modified peptide fragment derived from human growth hormone and is commonly researched for its potential role in fat metabolism and body composition support. Unlike full human growth hormone, AOD-9604 was designed to focus on the fat-metabolism portion of the molecule without producing the broader growth-related effects associated with HGH. It is often discussed as a weight loss peptide because of its potential influence on lipolysis, which is the breakdown of stored fat, and lipogenesis, which is the creation of new fat. AOD-9604 is commonly associated with fat loss support, metabolic health, and body recomposition, although human research remains limited compared with approved weight-management medications.
Evidence context
AOD-9604 evidence summary
Human clinical evidence
AOD-9604 has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
AOD-9604 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for AOD-9604 as Not FDA-approved for weight loss. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable / Oral
- Typical Dosage
- No established approved dosage; commonly referenced range is 250–500 mcg daily, with older oral research using 1–30 mg daily.
- Typical Frequency
- Once daily
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on AOD-9604.
Internal links
Related peptides
Frequently asked questions
What category is AOD-9604 in?
AOD-9604 is listed in the Weight Loss category on Peptidic.
What route is AOD-9604 associated with?
AOD-9604 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is AOD-9604 approved?
Peptidic lists the approval status for AOD-9604 as: Not FDA-approved for weight loss. Approval details can vary by indication and jurisdiction.
Interested in AOD-9604?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01